Canton

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Head and neck cancer2 trials
• Melanoma2 trials
• Cervical cancer1 trial
• Lung cancer1 trial
• Metastatic breast cancer1 trial
• Ovarian cancer1 trial

Phase

• Phase 1/22 trials
• Phase 21 trial

Status

• Terminated2 trials
• Active, not recruiting1 trial

Lead sponsor

• Ascendis Pharma Oncology Division A/S2 trials
• Ascendis Pharma A/S1 trial

Running trials

• Active, not recruiting

  A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies

  NCT05081609· Phase 1/2· Ascendis Pharma Oncology Division A/S· Source

Closed trials

• Terminated

  TransCon (TC) TLR7/8 Agonist, TC IL-2 β/γ, Pembrolizumab Prior to Surgery for Advanced Head and Neck Squamous Cell Carcinoma

  NCT05980598· Phase 2· Ascendis Pharma A/S· Source

• Terminated

  A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors

  NCT04799054· Phase 1/2· Ascendis Pharma Oncology Division A/S· Source